S&P 500 falls on pressure from retail stocks, weak jobless claims
In a recent transaction reported on April 24, 2025, Mark Lewis (JO:LEWJ) Anderson, a director at Sintx Technologies, Inc. (NASDAQ:SINT), acquired 5,000 shares of common stock. The purchase was made at a price of $2.36 per share, amounting to a total investment of $11,800. The timing appears favorable, as the stock has since risen to $3.31, marking a 32% weekly gain. InvestingPro data shows the company maintains a FAIR financial health score, with liquid assets exceeding short-term obligations. This transaction brings Anderson’s total direct ownership to 5,000 shares. The acquisition reflects Anderson’s continued involvement and interest in the company, which is based in Salt Lake City, Utah. With earnings scheduled for May 20 and the stock showing a 51% gain over the past six months, investors seeking deeper insights into insider trading patterns can access additional analysis through InvestingPro, which offers 10+ additional real-time insights for SINT.
In other recent news, SINTX Technologies has announced significant developments that could impact its strategic direction and market presence. The company completed a $5 million private placement, facilitated by H.C. Wainwright & Co., which will be used for working capital purposes. This funding round included the sale of shares and warrants, with securities offered solely to accredited investors. In leadership changes, Eric Olson has been appointed as the new Chairman of the Board, succeeding Dr. Sonny Bal, who remains a board member. Olson’s dual role as CEO and Chairman aligns with SINTX’s strategic focus on the medical device sector.
Additionally, SINTX has highlighted the biomechanical advantages of its silicon nitride material in a peer-reviewed study for spinal surgery, conducted with the SRM Institute of Science and Technology. The study suggests that silicon nitride offers reduced implant subsidence and improved stability compared to traditional materials. The company is pursuing partnerships to integrate silicon nitride into commercial spinal implant systems. These developments reflect SINTX’s ongoing efforts to expand its influence in the medical device market and enhance its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.